Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Cartesian Therapeutics, Inc. (RNAC) is a Biotechnology company based in US with a market capitalization of $238.9M. Revenue declined 92.8% year-over-year and free cash flow was negative at -$79.4M. This page tracks RNAC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 66 employees · IPO Jun 22, 2016
Valuation
Valuation & price
$7.38as of May 17, 2026· -46.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$238.9M
Market cap
-92.8%
Revenue growth (YoY)
100.0%
Gross margin
-$79.4M
Free cash flow (USD)
-$112.5M
Net debt
Net cash position
0.3%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 30, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Cartesian Therapeutics, Inc.'s market cap?
Cartesian Therapeutics, Inc. (RNAC) has a market capitalization of $238.9M.
What is RNAC's P/E ratio?
A meaningful P/E ratio is not available for RNAC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying RNAC stock?
SEC Form 4 filings show no open-market insider buys at Cartesian Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.